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Abstract
Objectives: To examine whether combined vitamin D and calcium supplementation improves insulin sensitivity, insulin
secretion, b-cell function, inflammation and metabolic markers.
Design: 6-month randomized, placebo-controlled trial.
Participants: Ninety-five adults with serum 25-hydroxyvitamin D [25(OH)D] #55 nmol/L at risk of type 2 diabetes (with
prediabetes or an AUSDRISK score $15) were randomized. Analyses included participants who completed the baseline and
final visits (treatment n= 35; placebo n= 45).
Intervention: Daily calcium carbonate (1,200 mg) and cholecalciferol [2,000–6,000 IU to target 25(OH)D .75 nmol/L] or
matching placebos for 6 months.
Measurements: Insulin sensitivity (HOMA2%S, Matsuda index), insulin secretion (insulinogenic index, area under the curve
(AUC) for C-peptide) and b-cell function (Matsuda index x AUC for C-peptide) derived from a 75 g 2-h OGTT; anthropometry;
blood pressure; lipid profile; hs-CRP; TNF-a; IL-6; adiponectin; total and undercarboxylated osteocalcin.
Results: Participants were middle-aged adults (mean age 54 years; 69% Europid) at risk of type 2 diabetes (48% with
prediabetes). Compliance was .80% for calcium and vitamin D. Mean serum 25(OH)D concentration increased from 48 to
95 nmol/L in the treatment group (91% achieved .75 nmol/L), but remained unchanged in controls. There were no
significant changes in insulin sensitivity, insulin secretion and b-cell function, or in inflammatory and metabolic markers
between or within the groups, before or after adjustment for potential confounders including waist circumference and
season of recruitment. In a post hoc analysis restricted to participants with prediabetes, a significant beneficial effect of
vitamin D and calcium supplementation on insulin sensitivity (HOMA%S and Matsuda) was observed.
Conclusions: Daily vitamin D and calcium supplementation for 6 months may not change OGTT-derived measures of insulin
sensitivity, insulin secretion and b-cell function in multi-ethnic adults with low vitamin D status at risk of type 2 diabetes.
However, in participants with prediabetes, supplementation with vitamin D and calcium may improve insulin sensitivity.
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Introduction
Low serum 25-hydroxyvitamin D [25(OH)D] concentrations
and dietary calcium intake have been associated with impaired
insulin sensitivity or secretion in people at high risk of type 2
diabetes [1,2]. Furthermore, several prospective epidemiological
studies [3], including our previous research [4], have shown that
low serum 25(OH)D concentrations are associated with an
increased risk of type 2 diabetes. However, data from randomized
controlled trials (RCTs) of vitamin D and/or calcium supplemen-
tation have been inconclusive. Some studies have reported a
beneficial effect on insulin sensitivity [5–9] and/or secretion
[6,10,11] whereas several others failed to demonstrate any effect
[12–23]. Among these studies, only one trial over 16 weeks has
investigated the combined effects of calcium and vitamin D
supplementation on insulin sensitivity and secretion in people at
high risk of type 2 diabetes [10]. It is thus clear that further well-
designed longer-term clinical trials are needed to evaluate the
efficacy of combined calcium and vitamin D supplementation on
type 2 diabetes risk.
The primary aim of this 6-month, double-blinded, placebo-
controlled randomized trial was to evaluate whether combined
calcium and vitamin D supplementation could improve insulin
sensitivity, insulin secretion and b-cell function in vitamin D-
deficient individuals at risk of type 2 diabetes. Secondary aims
were to evaluate the effects of supplementation on anthropometry,
blood pressure, the lipid profile, inflammation and metabolic
markers.
Materials and Methods
Study design
This was a 6-month, double-blinded, placebo-controlled trial
conducted at a single site (Western Hospital, Melbourne, Australia)
in which 95 participants stratified by age (,50 or $50 years), sex
and BMI (,30 or $30 kg/m2) in blocks of ten (block-stratified
randomization) were randomly allocated in a 1:1 ratio to either
combined calcium and vitamin D treatment or placebo.
Randomization was conducted by an independent researcher
using computer-generation randomization of study numbers
(Microsoft Excel). All investigators, research staff and participants
were blinded to the treatment allocation. The protocol for this trial
and supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Participants
Multi-ethnic vitamin D-deficient men and women aged $18
years and at risk of type 2 diabetes were recruited through
newspaper and radio advertisements, flyers posted in hospitals and
medical clinics as well as presentations given to local community
groups in the western Melbourne metropolitan area (Australia)
between January 2009 and February 2011. Participants were
included if they had a BMI between 25 and 40 kg/m2, a serum
25(OH)D concentration #50 nmol/L [24] and a diagnosis of
prediabetes (fasting plasma glucose 6.1–6.9 mmol/L and/or 2-h
plasma glucose post 75 g glucose load 7.8–11.0 mmol/L). During
the trial, changes in the inclusion criteria were approved by the
ethics committee to improve the recruitment rate: participants
were included if they had a serum 25(OH)D concentration #
55 nmol/L and if they either had a diagnosis of prediabetes or
scored $15 on the Australian Type 2 Diabetes Risk Assessment
tool (AUSDRISK). The AUSDRISK is a validated and simple 10-
point questionnaire that predicts the risk of type 2 diabetes (http://
www.health.gov.au/internet/main/publishing.nsf/Content/chronic-
diab-prev-aus). A score of 15 corresponds to a 10% probability of
diabetes in the next 5 years.
Participants were excluded based on the following criteria:
HbA1c $6.5%, pregnancy or breast-feeding, creatinine clearance
,60 ml/min, cirrhosis, malabsorption or elevated serum anti-
tissue transglutaminase antibody, hypercalcemia, hypercalciuria,
history of nephrolithiasis, previous non traumatic fractures, serum
25(OH)D ,13 nmol/L, active or chronic inflammation (based on
clinical assessment), medications known to affect glucose and
mineral metabolism over the last 3 months, pharmacological
treatment for obesity, commencement of physical activity $3
times/week or .5% change in weight in the last 3 months.
The study was approved by the Melbourne Health Human
Research Ethics Committee and the procedures followed were in
accordance with the ethical standards of the institution and the
declaration of Helsinki. The study was registered with the Australian
New Zealand Clinical Trials Registry (ACTRN12609000043235:
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
ACTRN=12609000043235). All participants provided written
informed consent.
Intervention
The treatment group commenced on 2,000 IU of vitamin D3
(two capsules of 1,000 IU of OstevitD, Key Pharmaceuticals,
Australia) plus 1,200 mg of elemental calcium (two capsules of
calcium carbonate, Wyeth Consumer Healthcare, Australia) daily
with breakfast. After 2 and 4 months, serum 25(OH)D was
measured and if necessary, the vitamin D3 dose was increased by
2,000 IU every 2 months to reach a target of$75 nmol/L. Serum
25(OH)D results were sent directly to the Western Health clinical
trial pharmacist who was responsible for applying the protocol.
The pharmacist dispensed all study supplements and performed
capsule count every 2 months. To maintain blinding, extra vitamin
D placebo capsules were provided to participants to match a total
of four and six capsules starting at 2 and 4 months, respectively.
The placebo group was given matching calcium placebo capsules
as well as 2, 4 and 6 vitamin D placebo capsules daily at 0, 2 and 4
months, respectively (Stenlake Compounding Chemist, Australia).
Every 2 months, participants were asked about a change in their
medical condition or about side effects including symptoms of
vitamin D hypersensitivity. Finally, a colleague not involved in the
study performed safety monitoring of serum calcium every 2
months.
Measurements
The following measurements were performed at baseline and 6
months, unless stated.
Vitamin D, Calcium and Type 2 Diabetes Risk
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Anthropometry and blood pressure
Weight, height, waist circumference and blood pressure were
assessed every 2 months in the morning before performing the
biochemical tests. Weight was measured to the nearest 0.1 kg,
without shoes and in light clothing, using an electronic calibrated
scale. Height was measured to the nearest 0.1 cm using a wall-
mounted stadiometer. BMI was calculated in kg/m2. Waist
circumference was measured in duplicate to the nearest 0.5 cm
using a tape placed at the midpoint between the lower rib and the
upper iliac crest, at the end of a normal expiration. Seated blood
pressure was measured in triplicate, after 5 minutes of rest in a
quiet room. For all measures, the average of multiple measure-
ments was calculated.
Diet, physical activity and sunlight exposure
To estimate dietary calcium and vitamin D intake, a calcium-
specific food frequency questionnaire, developed and validated in
Australia, was adapted by adding major dietary sources of vitamin
D [25]. Daily intakes were estimated using Australian-specific
dietary software (FoodWorks, Xyris Software, Australia). The
short International Physical Activity Questionnaire was used to
estimate physical activity habits over the last week. The sum of
metabolic equivalent of task (MET)-minutes per week spent
walking and doing moderate and vigorous physical activity was
calculated based on the updated Compendium of Physical
Activities [26] and the 2005 IPAQ guidelines (http://www.ipaq.
ki.se/scoring.pdf). A sun exposure questionnaire was administered
to estimate weekly exposure to sunlight over the last 2 months.
Participants were asked how many hours per week they spent in
the sun between 9 am and 5 pm, how often they used sunscreen ($
50% or ,50% of the time) and the degree of clothing worn when
outside (shirt/hat/pants/skirt) to determine the fraction of body
surface area exposed to sunlight. A sun index was calculated as
follows: hours of sun exposure/week multiplied by the fraction of
the body surface area exposed. Based on the month of blood
testing at baseline, participants were divided into two groups:
spring/summer (in Australia from October to March) and fall/
winter (from September to April).
Measures of insulin sensitivity, insulin secretion and b-cell
function
A 75-g 2-h oral glucose tolerance test (OGTT) was performed in
the morning after a 12-h fast. Venous blood was collected through
a catheter at 230, 220, 210, 0, 10, 20, 30, 60, 90 and 120
minutes for the determination of plasma glucose, serum insulin
and C-peptide. Measures at times 230, 220, 210 and 0 minutes
were averaged to derive fasting values. HOMA2%S and Matsuda
indices were used to evaluate insulin sensitivity. HOMA2%S was
calculated using the HOMA calculator (http://www.dtu.ox.ac.uk)
while Matsuda was calculated with the following formula: 10,000
divided by the square root of [(fasting glucose x fasting insulin) x
(mean glucose30–120 min x mean insulin30–120 min)]. The insulino-
genic index (delta C-peptide0–30 min divided by delta glucose0–
30 min) and the area under the curve (AUC) for C-peptide were
used to estimate insulin secretion. b-cell function was assessed
using the disposition index and calculated by multiplying Matsuda
index by AUC for C-peptide. Glucose was measured enzymati-
cally by the hexokinase method (Roche c701), while insulin and C-
peptide were measured by electrochemiluminescence immunoas-
says (Roche e602).
Serum 25-hydroxyvitamin D, parathyroid hormone,
inflammatory and metabolic markers
Serum was stored at 280uC until measurements were
performed in a single batch for each measure at the end of the
study. All biochemical markers were assessed at 0 and 6 months,
except for serum 25(OH)D which was assessed every 2 months.
Serum 25(OH)D was analysed by an automated chemiluminescent
immunoassay (DiaSorin, USA, CV 6.6%). Parathyroid hormone
was assessed by electrochemiluminescence immunoassay (Roche
e602) and high-sensitive C-reactive protein (hs-CRP) by immuno-
turbidimetric immunoassay (Roche c701). Lipid profiles were
measured using standard methods (Roche c701). Serum IL-6 and
TNF-a were measured by a chemiluminescent enzyme immuno-
assay (Immulite, Siemens, USA). Glycated haemoglobin (HbA1c)
was assessed by a DCCT-aligned ion exchange HPLC method
(Bio-Rad Variant II Turbo 2.0 analysers, CV 1.6%). Adiponectin
was measured by ELISA (R&D Systems, USA) and total
osteocalcin by the automated Elecsys assay (Roche, Australia).
Undercarboxylated osteocalcin was measured using the same
automated assay described for total osteocalcin. However,
measurement was preceded by sample pre-treatment with a
100 mg/mL hydroxyapatite slurry, following the method de-
scribed by Gundberg [27].
Statistical analysis
Analyses were performed using SAS statistical software version
9.2 (SAS Institute, Cary, NC, USA). Data were analyzed on all
participants who completed the baseline and final visits regardless
of compliance. No data was imputed for the few participants with
missing data (n=4). Data not following normal distribution were
log-transformed prior to analysis. Baseline characteristics of the
participants were compared between treatment groups using an
unpaired t test or a chi-square test, as appropriate. A multivariate
2-factor repeated-measures regression analysis was used to assess
time effects and time-by-treatment interactions effect on all
outcome measures after adjustment for the variables that were
different between treatment groups at baseline with a P value #
0.10 (fasting glucose, waist circumference, season of recruitment,
prediabetes status, systolic and diastolic blood pressure, hs-CRP,
IL-6, current smoking and dietary vitamin D intake). For IL-6,
which was non-normally distributed after transformation, an
ANOVA on rank was used to detect between-group differences
after adjusting for variables that were different between groups at
baseline. A post hoc analysis was performed on the participants
who had prediabetes based on the first study visit 2-h OGTT. This
analysis thus excluded participants with normal glucose tolerance
or newly diagnosed type 2 diabetes. In this subgroup, baseline
characteristics of the participants were not different between
treatment groups and thus unadjusted data are presented.
Based on the difference in delta HOMA-IR [0.1560.18 (SD)]
observed in a population of overweight men and women with
prediabetes before and after a mean weight loss of 9.8 kg [28], we
initially calculated that we would require a total of 80 participants
to detect this difference in HOMA-IR (that was considered
clinically significant) with a power of 90%, a 2-sided alpha of 0.05
and a dropout rate of 20%. Sample size estimates were then
recalculated based on a secondary analysis of a 3-year RCT which
reported that combined calcium and vitamin D supplementation
was associated with a 0.86 (standard deviation of 1.7) difference for
the change in HOMA-IR relative to placebo in older adults with
impaired fasting glucose [29]. Based on these findings, we
Vitamin D, Calcium and Type 2 Diabetes Risk
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estimated that we would require 160 participants (80 per group) to
detect a difference of this magnitude at 80% power with a 2-sided
alpha of 0.05, and assuming a dropout rate of 20%. However, due
to slower participant recruitment than anticipated, recruitment
was stopped after the 95th participant was randomized.
Results
Participant characteristics
A flowchart showing participant enrollment, allocation, follow-
up and analysis is presented in Figure 1. A total of 885 people
were telephone-screened, of whom 510 were invited to undergo
further screening. Ninety-five participants met the study criteria
and were randomized (24 were screened with OGTT and 71 with
AUSDRISK questionnaire). For administrative purposes, ran-
domization was performed 24 to 72 h before the first study visit.
Eleven participants withdrew from the study for personal reasons
(not interested anymore) between randomization and the first
study visit (treatment n=7; placebo n=4), and thus had no
baseline data, leaving 84 participants who completed the baseline
study visit (treatment n=39; placebo n=45). Moreover, four
participants did not complete the last study visit (treatment n=4).
Reasons for withdrawal during the study were: pregnancy (n=1),
vasovagal reaction after attempts to insert a catheter during the
last study visit (n=1) and personal reasons (n=2). Comparison of
the 15 participants who withdrew and the 80 participants who
completed the study revealed that those who withdrew were
significantly younger (mean age 46 vs. 55 years, P=0.03), but
there was no difference between the groups for sex, ethnicity,
serum 25(OH)D concentrations, BMI, waist circumference and
AUSDRISK score at baseline.
Figure 1. Flowchart showing participant enrollment, allocation, follow-up and analysis.
doi:10.1371/journal.pone.0109607.g001
Vitamin D, Calcium and Type 2 Diabetes Risk
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Baseline characteristics of the 80 participants who completed
the baseline and final study visits are presented in Table 1.
Participants were on average 54 years of age, had a mean BMI of
31 kg/m2 and were mostly women of European background. After
inclusion, an OGTT was performed. Diabetes was diagnosed in
14% of the participants (n=11), 39% were glucose tolerant
(n=31) and 48% had prediabetes (impaired fasting glucose and/
or impaired glucose tolerance) (n=38). Baseline characteristics
were similar between treatment groups, with the exception that
those in the treatment group were more likely to be current
smokers, to start the study during spring/summer, to have higher
dietary vitamin D intake and have lower waist circumference,
systolic and diastolic blood pressure, fasting plasma glucose, hs-
CRP and IL-6 concentrations. They were also less likely to have
prediabetes.
Supplement compliance and change in serum 25(OH)D
concentration
Supplement compliance was similar between groups for calcium
(treatment 81%; placebo 76%) and vitamin D (treatment 85%;
placebo 80%). After 6 months, serum 25(OH)D increased by a
mean of 48 nmol/L (95% CI, 41–56 nmol/L) to reach a mean
concentration of 95 nmol/L (95% CI, 89–101 nmol/L) in the
treatment group; there was no change in the control group
(Figure 2). Overall, 91% of the participants in the treatment
group reached the target serum 25(OH)D of 75 nmol/L. Most
participants required 4,000 IU/d of vitamin D to reach the target
Table 1. Baseline characteristics of the participants by treatment group.
Characteristic Treatment (n=35) Placebo (n=45) P value*
Age, years 53.8 (11.9) 55.3 (11.1) 0.57
Women, % 71 67 0.65
Ethnicity, % 0.39
European background 69 69
Asian 23 29
Other 9 2
Season of recruitment, % 0.003
Spring/summer (Oct-Mar) 94 67
Fall/winter (Apr-Sep) 6 33
Current smoking, % 17 2 0.02
First degree relative with diabetes, % 66 76 0.23
AUSDRISK score{ 18.5 (3.3) 18.9 (3.3) 0.57
BMI{, kg/m2 31.1 (5.7) 31.9 (6.2) 0.61
Waist circumference, cm 103.0 (11.5) 108.4 (15.3) 0.08
Systolic blood pressure, mm Hg 120.8 (14.0) 126.8 (12.1) 0.05
Diastolic blood pressure, mm Hg 73.1 (10.0) 76.8 (8.9) 0.09
HbA1c, % 5.6 (0.4) 5.7 (0.4) 0.31
Fasting glucose, mmol/L 5.2 (0.5) 5.5 (0.6) 0.04
Fasting insulin, mU/mL 12.6 (7.1) 15.2 (7.6) 0.11
Prediabetes`, % 37 56 0.10
Impaired fasting glucose ($6.1 mmol/L), % 0 11 0.04
Impaired glucose tolerance, % 37 53 0.15
25-hydroxyvitamin D, nmol/L 47 (13) 43 (13) 0.25
Parathyroid hormone{, pmol/L 5.3 (2.0) 5.5 (1.8) 0.63
Corrected calcium, mmol/L 2.15 (0.08) 2.16 (0.08) 0.59
Serum creatinine, mmol/L 68 (12) 69 (13) 0.90
Dietary vitamin D intake{, IU/day 132 (76) 108 (60) 0.08
Dietary calcium intake, mg/day 689 (419) 563 (275) 0.13
Physical activity, MET-min/week 2171 (3238) 1811 (2428) 0.55
Time spent outdoor{, h/day 1.8 (1.4) 1.8 (1.5) 0.88
Sun index{, h/week/m2 158 (233) 152 (218) 0.58
Sunscreen use ,50% of the time, % 66 69 0.76
Data are presented as mean (SD) or %.
*Unpaired t test or chi-square test, as appropriate.
{Logarithmically-transformed variables.
`Comprises participants with impaired fasting glucose and/or impaired glucose tolerance.
BMI, body mass index; MET, metabolic equivalent of task.
doi:10.1371/journal.pone.0109607.t001
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(n=22) while a smaller proportion needed 2,000 IU/d (n=9) or
6,000 IU/d (n=4).
Changes in insulin sensitivity, insulin secretion, b-cell
function, metabolic and inflammatory markers
There were no differences in the changes in any of the insulin
sensitivity or secretion measures, or in the disposition index,
between the treatment and placebo groups, even after taking into
account the variables that were different between groups at
baseline (fasting glucose, waist circumference, season of recruit-
ment, prediabetes status, systolic and diastolic blood pressure, hs-
CRP, IL-6, current smoking and dietary vitamin D intake)
(Table 2). Similarly, waist circumference and blood pressure
remained stable for both groups during the intervention. There
was however a borderline significant time-by-treatment interaction
for body weight due to a small but non-significant 0.49 kg increase
in the placebo group that was observed only in the adjusted model
(Table 3). There were no between group differences in blood
lipids, markers of inflammation, adiponectin, total and under-
carboxylated osteocalcin concentrations (Table 4). In a post hoc
analysis restricted to participants with prediabetes, there was a
significant between group difference for the change in insulin
sensitivity, as assessed by HOMA%S and Matsuda, in favor of the
vitamin D and calcium supplementation group (Table 5). There
were however no between group differences for the change in
markers of insulin secretion or b-cell function.
Safety
None of the participants discontinued the study because of side
effects associated with treatment. Two participants in the
treatment group developed asymptomatic mild hypercalcemia
(2.56 and 2.57 mmol/L) at the 2-month visit. Furthermore, five
participants in the treatment and two in the placebo group
developed hypercalciuria (.10 mmol/d). However, none reported
episodes of nephrolithiasis. Other common complaints included:
gastrointestinal issues (treatment, n=11; placebo, n=17), fatigue
(treatment, n=2; placebo; n=3) and musculoskeletal symptoms
(treatment, n=2; placebo, n=2).
Figure 2. Mean (SD) serum 25-hydroxyvitamin D concentra-
tions at baseline and after 2, 4 and 6 months in the calcium and
vitamin D treatment and placebo group. *P,0.0001 for the
difference between groups.
doi:10.1371/journal.pone.0109607.g002
Table 2. Mean baseline and 6 month values and the mean absolute changes in insulin sensitivity, insulin secretion and b-cell
function in the treatment and placebo group.
Mean Change P value*
Baseline 6 months (95% CI) Time Treatment Interaction
HOMA2%S{
Treatment (n= 34) 63.9 (29.0) 61.1 (25.6) 22.8 (29.2, 3.5) 0.01 (0.29) 0.96 (0.10) 0.11 (0.68)
Placebo (n=45) 55.1 (30.4) 52.5 (27.7) 22.6 (28.2, 3.0)
Matsuda index
Treatment (n= 33) 49.0 (25.8) 47.3 (21.5) 21.7 (27.3, 3.8) 0.40 (0.37) 0.89 (0.12) 0.59 (0.87)
Placebo (n=45) 40.5 (25.8) 39.3 (22.3) 21.2 (25.1, 2.8)
Insulinogenic index, mU/mL/mmol/L mmU/mL mU/mL
Treatment (n= 33) 0.51 (0.28) 0.52 (0.25) 0.01 (20.07, 0.10) 0.22 (0.67) 0.47 (0.47) 0.67 (0.89)
Placebo (n=45) 0.55 (0.23) 0.56 (0.30) 0.01 (20.05, 0.06)
AUC for C-peptide, nmol/L6120 min
Treatment (n= 33) 410.8 (138.8) 418.0 (123.2) 7.2 (214.1, 28.5) 0.71 (0.97) 0.39 (0.10) 0.75 (0.44)
Placebo (n=43) 463.8 (132.7) 455.8 (97.3) 28.0 (238.6, 22.7)
Disposition index, nmol/L6120 min`
Treatment (n= 33) 17 568 (4 936) 17 863 (5 010) 295 (2861, 1 451) 0.90 (0.70) 0.30 (0.09) 0.71 (0.31)
Placebo (n=43) 16 926 (7 605) 16 656 (7 356) 2270 (21 502, 960)
Baseline and 6 month data are presented as mean (SD).
*A multivariate 2-factor repeated-measures regression analysis was used to assess time effects and time by treatment effect interactions on all outcome variables after
adjustment for the variables that were different between treatment groups at baseline. Numbers in brackets represent unadjusted P values.
{Logarithmically-transformed variables.
`Calculated by multiplying Matsuda index by AUC for C-peptide.
AUC, area under the curve; HOMA2%S, Homeostasis Model Assessment 2 index of insulin sensitivity.
doi:10.1371/journal.pone.0109607.t002
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Discussion
In this 6-month RCT of vitamin D and calcium supplemen-
tation in which over 90% of the participants reached the target
serum 25(OH)D concentration of 75 nmol/L, there was no effect
of supplementation on any measure of insulin sensitivity, insulin
secretion or b-cell function in multi-ethnic vitamin D-deficient
individuals at risk of type 2 diabetes (with prediabetes or an
AUSDRISK score $15). Moreover, supplementation did not
improve cardiovascular disease risk factors such as blood pressure
and lipid profile, and had no effect on any inflammatory marker,
adiponectin or osteocalcin concentrations. However, in a post hoc
analysis restricted to participants with prediabetes (48% of the
participants), there was a significant beneficial effect of vitamin D
and calcium supplementation on insulin sensitivity, but not on
insulin secretion or b-cell function. The results of this pilot study
suggest that combined supplementation with calcium and vitamin
D in multi-ethnic vitamin D-deficient men and women at risk of
type 2 diabetes (based on a diabetes risk questionnaire) may not be
an effective strategy to delay or prevent type 2 diabetes. However,
in those with prediabetes, there could be a beneficial treatment
Table 4. Mean baseline and 6 month values and the mean absolute changes in lipid profile, cytokines, adiponectin and
osteocalcin in the treatment and placebo group.
Mean Change P value*
Baseline 6 months (95% CI) Time Treatment Interaction
Total cholesterol, mmol/L{
Treatment (n= 32) 5.16 (1.19) 5.10 (1.36) 20.06 (20.39, 0.28) 0.80 (0.01) 0.21 (0.45) 0.42 (0.11)
Placebo (n=42) 5.11 (0.99) 4.69 (1.06) 20.42 (20.65, 20.19)
Triglycerides, mmol/L{
Treatment (n= 32) 1.56 (0.96) 1.62 (0.93) 0.06 (20.20, 0.33) 0.47 (0.36) 0.24 (0.92) 0.32 (0.09)
Placebo (n=42) 1.57 (0.72) 1.41 (0.67) 20.16 (20.33, 0.01)
HDL-cholesterol, mmol/L
Treatment (n= 32) 1.28 (0.29) 1.27 (0.33) 20.01 (20.07, 0.05) 0.91 (0.98) 0.81 (0.75) 0.47 (0.61)
Placebo (n=42) 1.29 (0.33) 1.31 (0.41) 0.02 (20.06, 0.09)
LDL-cholesterol, mmol/L
Treatment (n= 32) 3.17 (0.99) 3.11 (1.19) 20.06 (20.34, 0.23) 0.68 (0.01) 0.26 (0.35) 0.29 (0.36)
Placebo (n=42) 3.10 (0.93) 2.76 (0.91) 20.34 (20.53, 20.17)
Hs-CRP, mg/L{
Treatment (n= 34) 5.52 (10.82) 3.62 (5.68) 21.90 (25.14, 1.34) 0.97 (0.54) 0.07 (0.10) 0.80 (0.51)
Placebo (n=45) 2.44 (2.15) ` 2.57 (2.66) 0.13 (20.31, 0.57)
TNF-a, pg/mL{
Treatment (n= 34) 6.31 (2.18) 6.60 (1.43) 0.29 (20.28, 0.87) 0.82 (0.02) 0.56 (0.29) 0.39 (0.83)
Placebo (n=45) 6.70 (2.43) 7.10 (2.27) 0.40 (20.17, 0.97)
IL-6, pg/mL1
Treatment (n= 34) 1.2 (1.2, 2.1) 1.3 (1.2, 1.8) 0.0 (20.4, 0.1) NA 0.44 (0.42) NA
Placebo (n=45) 1.8 (1.4, 2.4) ` 1.9 (1.4, 2.8) 0.0 (20.4, 0.5)
Total adiponectin, ng/mL{
Treatment (n= 34) 6070 (3613) 6197 (3954) 127 (2407, 662) 0.59 (0.95) 0.94 (0.99) 0.34 (0.52)
Placebo (n=45) 6424 (4408) 6333 (4385) 291 (2665, 484)
Total osteocalcin, ng/mL
Treatment (n= 34) 17.5 (6.3) 16.7 (7.7) 20.8 (22.3, 0.8) 0.59 (0.15) 0.43 (0.10) 0.58 (0.92)
Placebo (n=45) 20.1 (7.8) 19.4 (8.1) 20.7 (22.0, 0.6)
Undercarboxylated osteocalcin, ng/mL
Treatment (n= 34) 11.3 (4.0) 11.0 (4.5) 20.3 (21.4, 0.8) 0.70 (0.45) 0.44 (0.10) 0.57 (0.94)
Placebo (n=45) 13.1 (5.0) 12.9 (5.3) 20.2 (21.1, 0.6)
Baseline and 6 month data are presented as mean (SD).
*A multivariate 2-factor repeated-measures regression analysis was used to assess time effects and time by treatment effect interactions on all outcome variables after
adjustment for the variables that were different between treatment groups at baseline. Numbers in brackets represent unadjusted P values.
{ogarithmically-transformed variables.
`P,0.1 for the difference between groups at baseline (unpaired t test or Wilcoxon, as appropriate).
1Variables not respecting normality even after transformation are presented as median (25th, 75th percentile) and an ANOVA on rank was used to assess treatment
effects (adjusted for variables that were different between treatment groups at baseline).
hs-CRP, high sensitive C-reactive protein; IL-6, interleukin-6; NA, not applicable; TNF-a, tumor necrosis factor-alpha.
doi:10.1371/journal.pone.0109607.t004
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effect on insulin sensitivity, but these results need to be interpreted
with caution given the post hoc nature of the analysis.
The findings from numerous prospective observational studies,
including our previous research in over 5,000 Australian adults
followed for 5 years, have consistently shown that low vitamin D
status is an independent risk factor for type 2 diabetes [3,4].
However, prospective observational studies looking at the associ-
ation between insufficient calcium intake and type 2 diabetes risk
have shown mixed results [4,30–33]. To our knowledge, only one
RCT has evaluated the effects of combined calcium and vitamin D
supplementation on insulin sensitivity, insulin secretion and b-cell
function in people with glucose intolerance or early diabetes [10],
but three others have been conducted in people with type 2
diabetes [6,9,18]. In a 262 factorial trial of vitamin D3 (2,000 IU/
d) and calcium (800 mg/d) supplementation for 4 months in 92
mostly Caucasian individuals with prediabetes or early diabetes,
Mitri et al. found no change in insulin sensitivity in all the
treatment groups using the intravenous glucose tolerance test [10].
However, a significant although small improvement in insulin
secretion and b-cell function was demonstrated, and there was a
trend toward an attenuation of the rise in HbA1c in the vitamin D3
supplementation groups, with or without calcium. Supplementa-
tion with calcium alone did not change insulin secretion or
sensitivity. On the other hand, Nikooyeh et al. reported an
improvement in insulin resistance (HOMA-IR) in Iranian men
and women with type 2 diabetes who consumed a calcium- and
vitamin D3-fortified yogurt (CDY) containing 1,000 IU of vitamin
D3 plus 500 mg of calcium daily or a vitamin D3-fortified yogurt
(DY) containing 1,000 IU of vitamin D3 and 300 mg of calcium
daily as opposed to a plain yogurt (PY) containing 300 mg of
calcium daily for 3 months [6]. Similarly, Shab-Bidar et al. found
an increase in insulin sensitivity (Quicki) in Iranians with type 2
diabetes who consumed a DY containing 1000 IU of vitamin D3
daily versus a PY containing 325 mg of calcium daily for 3 months
[9]. In contrast, no change in HOMA-IR was observed in vitamin
D-deficient Koreans with type 2 diabetes receiving 2,000 IU of
vitamin D3 and 200 mg of calcium daily for 6 months [18]. Both
the studies by Mitri and Nikooyeh suggest that benefits on
glycemic outcomes come from vitamin D and that adding calcium
does not provide further improvement. However, of the RCTs of
vitamin D supplementation alone that evaluated surrogate
markers of type 2 diabetes risk, only three found an increase in
insulin sensitivity [5,7,8] while the remainder did not find an effect
on either insulin sensitivity or secretion [12–17,19–23,34].
The discordant results reported on the effects of vitamin D and/
or calcium supplementation on insulin sensitivity and secretion do
not seem to be fully explained by factors such as baseline vitamin
D status, duration of treatment or vitamin D dose. Indeed, most
studies recruited participants with baseline serum 25(OH)D
concentrations ranging from 30 to 40 nmol/L. Moreover, positive
results on glucose homeostasis have been reported after only 6
weeks of treatment [5] while no effect has been observed after 12
months [13,15,17]. In addition, although vitamin D doses varied
from 400 IU daily to 88,865 IU per week, several studies,
including the current trial, reached a target serum 25(OH)D
concentration of .75 nmol/L [8,15,34]. A factor that could
explain the heterogeneous results obtained from RCTs of vitamin
D with or without calcium supplementation is the choice of the
population studied in terms of diabetes risk. Our study suggests
that those with prediabetes may improve insulin sensitivity with
Table 5. Mean baseline and 6 month values and the mean absolute changes in insulin sensitivity, insulin secretion and b-cell
function in the subgroup of participants with prediabetes.
Mean Change P value*
Baseline 6 months (95% CI) Time Treatment Interaction
HOMA2%S{
Treatment (n= 13) 58.5 (23.4) 59.0 (25.3) 0.5 (212.0, 13.1) 0.17 0.04 0.18
Placebo (n=25) 47.6 (22.6) 42.2 (22.5) 25.5 (211.0, 0.1)
Matsuda index
Treatment (n= 13) 41.9 (18.7) 44.1 (22.3) 2.1 (26.2, 10.4) 0.97 0.04 0.29
Placebo (n=25) 32.8 (14.7) 30.8 (13.6) 22.0 (26.0, 2.0)
Insulinogenic index, mU/mL/mmol/L mmU/mL mU/mL
Treatment (n= 13) 0.52 (0.21) 0.49 (0.19) 20.03 (20.09, 0.03) 0.39 0.84 0.62
Placebo (n=23) 0.52 (0.23) 0.52 (0.23) 20.01 (20.07, 0.05)
AUC for C-peptide, nmol/L6120 min
Treatment (n= 13) 453.7 (167.8) 456.6 (152.8) 2.9 (230.2, 36.0) 0.65 0.57 0.49
Placebo (n=24) 487.3 (132.1) 473.9 (97.6) 213.4 (245.0, 18.2)
Disposition index, nmol/L6120 min`
Treatment (n= 13) 16796 (4760) 17634 (5306) 838 (21419, 3095) 0.98 0.06 0.17
Placebo (n=24) 14591 (4418) 13730 (5073) 2861 (22306, 584)
Baseline and 6 month data are presented as mean (SD).
*A 2-factor repeated-measures regression analysis was used to assess time effects and time by treatment effect interactions on all outcome variables.
{Logarithmically-transformed variables.
`Calculated by multiplying Matsuda index by AUC for C-peptide.
AUC, area under the curve; HOMA2%S, Homeostasis Model Assessment 2 index of insulin sensitivity.
doi:10.1371/journal.pone.0109607.t005
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calcium and vitamin D supplementation. However, other studies
failed to demonstrate an effect of vitamin D supplementation in
this population [11,15,22]. People with normal glucose tolerance
or at lower risk of type 2 diabetes are unlikely to benefit from
treatment [12,13,16,23,34]. However, it remains unclear whether
people with type 2 diabetes may improve glucose homeostasis with
calcium and/or vitamin D supplementation [6,9–11,17–21,35].
Another variable that may explain the discrepant results observed
between studies is the presence of polymorphisms in the vitamin D
receptor (VDR) gene, and in genes affecting vitamin D and
glucose metabolism. Indeed, it was recently demonstrated that
individuals presenting certain VDR polymorphisms may be low
responders to vitamin D supplementation in terms of improvement
in serum 25(OH)D concentrations, insulin sensitivity and inflam-
mation [36,37]. Although we do not have data to support this, it is
possible that common genetic variants affecting glucose homeo-
stasis (e.g. IRS-1) and vitamin D status (e.g. those involved in skin
production of vitamin D, in vitamin D-binding protein concen-
trations and vitamin D catabolism) may also alter treatment
response [38]. Finally, baseline calcium intake may also affect
response to treatment. Results from Mitri et al. [10] and from our
study in which total calcium intake was between 1,800 and
2,000 mg daily suggest that increasing total calcium intake above
the recommended daily allowance may not improve insulin
sensitivity.
We found no beneficial effect of combined calcium and vitamin
D supplementation for 6 months on anthropometry, blood
pressure, lipid measures, inflammation or metabolic markers.
Our results are in line with the majority of previous RCTs that
have examined the effect of vitamin D and/or calcium supple-
mentation on cardiovascular disease risk factors [5,7,12,13,34].
Among the few studies that have shown significant reductions in
anthropometric measures, serum triglycerides, inflammatory
markers or adiponectin concentrations with supplementation
[6,9,39,40], most studied calcium and vitamin D integrated into
a yogurt drink [6,9], suggesting that these benefits may come from
dairy. A recent meta-analysis revealed that dairy product
consumption reduced body weight and fat [41]. Finally, despite
animal and human data suggesting that total and undercarboxy-
lated osteocalcin can regulate glucose homeostasis [42,43], we
found no evidence that vitamin D and calcium supplementation
alter this pathogenesis pathway.
Our study has several important strengths. First, this is one of
the few RCTs of combined calcium and vitamin D supplemen-
tation. Furthermore, we used an escalation regimen of vitamin D
that achieved the target serum 25(OH)D concentration of
75 nmol/L in 91% of our participants. It is worth noting that
most participants required large doses of vitamin D (4,000 IU per
day) to reach this serum 25(OH)D target. It is indeed well known
that obese individuals need larger doses of vitamin D, which is
possibly due to the sequestration of vitamin D in adipose tissue
[44]. Alternatively, the amount of vitamin D contained in the
supplements may have been less than what was claimed by the
manufacturer but we did not assess this possibility. Finally, we
evaluated several cardiometabolic risk factors and investigated
potential mechanisms by which vitamin D and calcium could
improve insulin secretion and sensitivity.
However, there are several limitations. First, we did not reach
our target sample size. We calculated that with 80 participants, our
power to detect a difference of 0.86 in delta HOMA-IR between
the treatment and placebo groups was 60%. It is thus possible that
our study did not have the power to find an effect of treatment.
With the small change in HOMA%S that we observed between
groups, a sample size of 2,012 participants would be required to
find an effect of treatment. Noteworthy, if only participants with
prediabetes were recruited, the sample size would be reduced to
285 participants given the larger difference in HOMA%S
observed after 6 months in this high-risk group. Future studies
should thus aim at recruiting high-risk individuals with prediabetes
and plan a longer follow-up. Second, because we did not reach our
target sample size, successful randomization was not achieved and
unbalanced distributions and proportions of some factors were
found between the treatment groups. Although we adjusted our
analyses for the variables that were different between treatment
groups at baseline, we cannot exclude that residual confounding
remains from measured and unmeasured factors, which could
invalidate our null results. Third, 16% of the participants dropped
out of the study. Although comparison between those who
dropped out and those who completed the trial did not reveal
differences in baseline characteristics except for age, our selected
population may not be representative of the general population.
Fourth, none of the participants had a baseline serum 25(OH)D
concentration ,20 nmol/L and only 10% had a value ,
30 nmol/L and thus we cannot exclude that vitamin D
supplementation would be beneficial in a population with severe
vitamin D deficiency. Fifth, our participants received a high total
calcium intake from diet and supplements for 6 months.
Therefore, we cannot extrapolate our results to a population with
low calcium intake. Sixth, we did not assess dietary vitamin A
intake, which could potentially interact with vitamin D to alter its
efficacy [45]. Moreover, we did not use the gold standard method
to evaluate insulin sensitivity, the euglycemic-hyperinsulinemic
clamp. Finally, although our study was one of the longest to date, it
remains possible that the benefits of calcium and vitamin D
supplementation may appear beyond 6 months.
Conclusions
In conclusion, this study has shown that supplementation with
calcium and vitamin D for 6 months may not improve insulin
sensitivity, insulin secretion, b-cell function or cardiovascular risk
factors in multi-ethnic vitamin D-deficient individuals at risk of
type 2 diabetes based on a diabetes risk questionnaire. However,
there may be a benefit of treatment on insulin sensitivity in
participants with prediabetes. Longer-term RCTs of vitamin D
and calcium supplementation focusing on individuals with
prediabetes and examining surrogate markers of type 2 diabetes
using gold-standard measures as well as measuring the incidence of
type 2 diabetes are required to better ascertain whether this could
be a safe and effective strategy to prevent type 2 diabetes. Genetic
variants also need to be assessed to determine whether subgroups
of the population may benefit from this intervention.
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